Dolutegravir/abacavir/lamivudine versus current ART in virally suppressed patients (STRIIVING): a 48-week, randomized, non-inferiority, open-label, Phase IIIb study.,Antiviral Therapy

当前位置： X-MOL 学术 › Antivir. Ther. › 论文详情

Our official English website, www.x-mol.net, welcomes your feedback! (Note: you will need to create a separate account there.)

Dolutegravir/abacavir/lamivudine versus current ART in virally suppressed patients (STRIIVING): a 48-week, randomized, non-inferiority, open-label, Phase IIIb study.
Antiviral Therapy ( IF 1.3 ) Pub Date : 2017-04-12 , DOI: 10.3851/imp3166
Benoît Trottier ₁ , Jordan E Lake ₂ , Ken Logue ₃ , Cynthia Brinson ₄ , Lizette Santiago ₅ , Clare Brennan ₆ , Justin A Koteff ₆ , Brian Wynne ₇ , Judy Hopking ₈ , Catherine Granier ₈ , Michael Aboud ₉

Affiliation

Simplified dosing regimens are important for patients who face challenges in adhering to HIV-1 therapy. We investigated the safety and virological efficacy of switching to once-daily abacavir/dolutegravir/lamivudine (ABC/DTG/3TC).

中文翻译：

在病毒抑制患者中，Dolutegravir / abacavir / lamivudine与目前的ART相比（STRIIVING）：一项为期48周的随机，非劣效，开放标签的IIIb期研究。

对于在坚持HIV-1治疗方面面临挑战的患者，简化给药方案非常重要。我们调查了每天换用阿巴卡韦/杜鲁格韦/拉米夫定（ABC / DTG / 3TC）的安全性和病毒学功效。

更新日期：2020-08-21

点击分享查看原文

点击收藏

公开下载

阅读更多本刊最新论文本刊介绍/投稿指南11